Dapivirine for HIV1 PrEP Ring A Vaginal Ring Containing Dapivirine for HIV1 PrEP Ring Study Background Source Nel A et al N Engl J Med 2016375 213343 Placebo Ring ID: 1020339
Download Presentation The PPT/PDF document "A Vaginal Ring Containing" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
1. A Vaginal Ring Containing Dapivirine for HIV-1 PrEP Ring
2. A Vaginal Ring Containing Dapivirine for HIV-1 PrEPRing Study: BackgroundSource: Nel A, et al. N Engl J Med. 2016;375:2133-43. Placebo Ring(n = 652)Dapivirine Ring(n = 1,307)Study Design: RingBackground: Randomized, double-blind, phase 3, placebo-controlled trial of a dapivirine-containing vaginal ring changed every 4 weeks as compared to a placebo ring for HIV-1 prevention for women at multiple sites in 7 communities in South Africa and UgandaInclusion Criteria (1,959 enrolled)- 18-45 years of age- HIV seronegative- Sexually active- Nonpregnant and on stable contraceptiveTreatment Arms:- Dapivirine 25 mg vaginal ring, changed monthly- Placebo vaginal ring, changed monthly1x2x
3. A Vaginal Ring Containing Dapivirine for HIV-1 PrEPRing Study: ResultsIncidence Rate for New HIV InfectionsSource: Nel A, et al. N Engl J Med. 2016;375:2133-43. P = 0.04⇓ 31%
4. A Vaginal Ring Containing Dapivirine for HIV-1 PrEPRing Study: ResultsRelative Reduction, by Age GroupSource: Nel A, et al. N Engl J Med. 2016;375:2133-43.
5. A Vaginal Ring Containing Dapivirine for HIV-1 PrEPRing Study: ConclusionsSource: Nel A, et al. N Engl J Med. 2016;375:2133-43. Conclusions: “Among women in sub-Saharan Africa, the dapivirine ring was not associated with any safety concerns and was associated with a rate of acquisition of HIV-1 infection that was lower than the rate with placebo.“
6.